This study aimed to understand the differences in clinical,epidemiological,and laboratory features between the new coronavirus disease 2019(COVID-2019)and influenza A in children.Data of 23 hospitalized children with ...This study aimed to understand the differences in clinical,epidemiological,and laboratory features between the new coronavirus disease 2019(COVID-2019)and influenza A in children.Data of 23 hospitalized children with COVID-19(9 boys,5.7±3.8 years old)were compared with age-and sexmatched 69 hospitalized and 69 outpatient children with influenza A from a hospital in China.展开更多
INTRODUCTIONThe National Health and Family Planning Commission of People＇s Republic of China released the ＂Regulations on canceling the admission approval of the third class medical technologies and relevant works＂...INTRODUCTIONThe National Health and Family Planning Commission of People＇s Republic of China released the ＂Regulations on canceling the admission approval of the third class medical technologies and relevant works＂ in July 2015. According to the new regulation, the obligations and responsibilities of health administration departments for the admission approval of the clinical applications on the third- and the second-class medical technologies will be transferred to medical institutions that perform the operations.展开更多
文摘This study aimed to understand the differences in clinical,epidemiological,and laboratory features between the new coronavirus disease 2019(COVID-2019)and influenza A in children.Data of 23 hospitalized children with COVID-19(9 boys,5.7±3.8 years old)were compared with age-and sexmatched 69 hospitalized and 69 outpatient children with influenza A from a hospital in China.
文摘INTRODUCTIONThe National Health and Family Planning Commission of People＇s Republic of China released the ＂Regulations on canceling the admission approval of the third class medical technologies and relevant works＂ in July 2015. According to the new regulation, the obligations and responsibilities of health administration departments for the admission approval of the clinical applications on the third- and the second-class medical technologies will be transferred to medical institutions that perform the operations.
